Abstract library

22 results for "bevacizumab".
#2875 Immunotherapy as Second-line Treatment in Grade 3 Neuroendocrine Carcinomas: A Prospective Case Series from an ENETS Center of Excellence
Introduction: Metastatic WHO grade 3 extra-pulmonary neuroendocrine carcinomas (EP-NEC) have a poor prognosis and optimal treatment after first-line platinum-etoposide chemotherapy remains unclear. A recent, small phase II study combining ipilimumab and nivolumab showed promising results
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - Targeted therapies
Presenting Author: Timon Vandamme
Keywords: NEC, immunotherapy
#55 Metronomic combination therapy including temozolamide, bevacizumab and somatostatin analogue for the treatment of malignant gastroenteropancreatic neuroendocrine tumors
Introduction: Malignant gastroenteropancreatic neuroendocrine tumors (GEPNETS), mainly carcinoids, are not considered to be particularly chemotherapy-sensitive to conventional chemotherapeutic schemes. Long-standing evidence suggests these tumors to be highly vascularised and responsive to antiangiogenic strategies. Newest reports demonstrate benefit by the use of temozolamide, an oral alkylating agent similar to intravenous dacarbazine. The DNA repair enzyme O6-alkylguanine–DNA alkyltransferase (AGAT) confers cancer cell resistance to O6-alkylating agents such as temozolamide through its ability to remove methyl/alkyl groups from the O6-position of guanine, thus correcting drug-induced DNA damage.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: DR Anna Koumarianou
#77 Angiogenesis markers after hepatic artery embolization of liver metastases in patients with neuroendocrine tumors
Introduction: In the event of diffuse hepatic metastases, hepatic artery embolization (HAE) can be a successful treatment option in patients with well-differentiated neuroendocrine tumors (WNET). Although there are suggestions of activation of the angiogenesis by HAE, no information is available about the development of growth factors caused by vascular obstruction with embolization.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: MSc Catharina M Korse
Authors: Korse C M, Bonfrer J M, Taal B G, ...
#114 Downstaging of a gastroenteropancreatic neuroendocrine tumor after combination therapy of temozolomide, Bevacizumab and long-acting somatostatin analogs
Introduction: Patients with gastroenteropancreatic endocrine (GEP) tumors and progressive disease have been treated with several chemotherapeutic regimens with variable responses and considerable toxicity. Recent studies have shown that GEP tumors may respond to therapy with anti-angiogenic agents, mainly as a result of their increased vascularity.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Stavroula Antoniou
#151 Rationale for combining mTOR with other targeted agents in the treatment of neuroendocrine tumors
Introduction: Advanced neuroendocrine tumors (NETs) are aggressive and incurable with standard treatment. Many cellular targets are being evaluated in this patient population, including mammalian target of rapamycin (mTOR), a kinase that is the central regulator of several signaling pathways related to cell growth, angiogenesis, and bioenergetics. Because mTOR serves as a neoplastic switch activated by many cancer-related mutations, mTOR inhibition may have broad efficacy across tumor types, including NETs. Somatostatin analogs (SSAs) have long been used to treat carcinoid symptoms in NET patients. The SSA octreotide long-acting release (LAR) demonstrated significant antitumor effects against advanced midgut NETs in the phase III PROMID study.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Kjell Öberg
Authors: Öberg K, Yao J C, ...
#173 Temozolomide in Metastatic Bronchial Carcinoids
Introduction: Metastatic bronchial carcinoids are rare neoplasms, where efforts of medical treatment thus far have been disappointing. Temozolomide has, however, shown some activity in a small prior study.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Dr. Daniel P Lindholm
#253 Description and Treatment of GEP NETs in a Spanish Hospital During 10 Years
Introduction: In our area the GEP NET incidence is similar to that of gastric and exocrine pancreatic cancers consequently being important to know their characteristics and the most convenient therapeutic approach.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: MD Paula Jiménez Fonseca
#280 Sorafenib and Bevacizumab Combination Targeted Therapy in Advanced Neuroendocrine Tumor: A Phase II Study of the Spanish Neuroendocrine Tumor Group (GETNE0801)
Introduction: Sorafenib (S) and bevacizumab (B) as single agents have shown efficacy and acceptable toxicity in NETs phase II trials. S+B combination has shown manageable toxicity in phase I trials in solid tumors.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Mrs. Cristina Garrido
#314 Clinical Effect of Temozolomide-Based Chemotherapy in Poorly Differentiated Endocrine Carcinoma (PDEC) after Progression on First-Line Chemotherapy
Introduction: Patients with metastatic PDEC usually have a short survival. After first-line palliative chemotherapy, there are no established second-line treatments. Temozolomide has shown effect in other NETs.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Staffan Welin
#415 Bevacizumab Plus Octreotide and Metronomic Capecitabine in Patients with Metastatic Well-to-Moderately Differentiated Neuroendocrine Tumors. The XELBEVOCT Multicenter Phase II Study
Introduction: A phase II study was designed to assess the activity and safety of metronomic oral capecitabine, bevacizumab, and octreotide (Xelbevoct) in metastatic well-to-moderately differentiated neuroendocrine neoplasms (WMD-NEN). We also assessed the predictive role for progression free survival (PFS) of hypertension, proteinuria and vascular endothelial growth factor (VEGF) polymorphisms and the predictive role of vitamin D on proteinuria and PFS.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: MD, PhD Maria Pia Brizzi
Keywords: bevacizumab